Skip to main content
Clinical Trials/ACTRN12621000104853
ACTRN12621000104853
Completed
Phase 3

A randomised double-blind placebo-controlled study to evaluate the effect ofcurcumin on BDNF levels in otherwise healthy adults.

RDC Global Pty Ltd0 sites69 target enrollmentFebruary 2, 2021

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Brain-Derived Neurotrophic Factor in healthy adults
Sponsor
RDC Global Pty Ltd
Enrollment
69
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 2, 2021
End Date
July 26, 2021
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Male and females aged 18\-40 years old
  • Able to provide informed consent
  • Agree not to take other supplements (e.g. curcumin, iron, resveratrol, fish oil) that may affect BDNF for the duration of the trial and within 2 weeks prior to commencing the study

Exclusion Criteria

  • Iron deficient anaemia
  • Unstable or serious illness (e.g. kidney, liver, biliary, GIT, heart conditions, diabetes, thyroid gland function, malignancy, lung conditions, chronic asthma, mood disorders or neurological disorders such as MS)\*
  • Currently taking medications that may affect BDNF such as antidepressants or anxiety medications, or have taken within the previous 6 months
  • Prescribed/receiving anticoagulation therapy (e.g., coumadin, heparin)
  • Females who are either trying to conceive, pregnant or lactating
  • Any chronic menstrual disorders or menopausal changes
  • Alcohol consumption exceeding 21 drinks/week
  • Active smoker/e\-cigarettes/nicotine use, use recreational drugs
  • Any chronic gastrointestinal problems
  • History of eating disorders

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A randomised double-blind placebo-controlled study of energy, protein and micronutrients supplementation of elderly patients in active rehabilitation settingsutritional status in the elderlyNutritional, Metabolic, EndocrineNutritional status
ISRCTN01133608The Health Foundation (UK)445
Completed
Not Applicable
A randomised double-blind placebo-controlled study to investigate the possible role of Opiate Morphine (MST) in the treatment of chronic cough.
ISRCTN18474014Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)30
Completed
Not Applicable
A randomised double-blind placebo controlled study of adenosine given as a Bier's block for patients with neuropathic pain in the limbsSigns and Symptoms: PainSigns and SymptomsPain
ISRCTN86618747Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)30
Not yet recruiting
Phase 1
Effect PartySmart Variants in alcohol subjects.
CTRI/2021/03/032236The Himalaya Drug Company
Completed
Phase 2
A double-blind randomised placebo controlled study to evaluate the effects of different doses of testosterone from a Testosterone Metered-Dose Transdermal Spray (MDTS) on sexual function in premenopausal women with low libidoow libido in post menopausal women suffering from low serum testosteroneLow libido in post menopausal women suffering from low serum testosteroneReproductive Health and Childbirth - Menstruation and menopause
ACTRN12605000481673FemPharm Pty Ltd and/or Acrux DDS Pty Ltd200